Post on 04-Sep-2020
Donald J. Hagler, MD, FASCIProfessor of Pediatrics and Medicine
Mayo Clinic College of Medicine
Congenital Interventional Catheterization in ACHD
Friday, November 2, 12
Mayo Recent ExperienceACHD
Ø173 patients with ACHD studied 2011- mid 2012
Ø82 or 47% were interventional procedures excluding simple RV biopsy
ØMajority were ASDs(13) or PFO (35) device closure
Ø12 StentsØRotational 3D angiography and CT
correlations ave become more frequent2
Friday, November 2, 12
Preop CT
3
Friday, November 2, 12
Rotational 3D angiography
4
Friday, November 2, 12
Rotational 3D angiography
5
Friday, November 2, 12
Melody Valve Percutaneous pulmonary valve implantation
Ø31 Pulmonary valve implants in 30 pts. Of these one pt also had TV replaced at the same procedure
ØAges 6-79 yearsØTOF, DORV, Truncus, PA/PS,TGA,
RossØ9 Homografts, 17 tissue prosthesesØ10 Tricuspid tissue prostheses
replacedØ8 Mitral tissue prostheses replaced 6
Friday, November 2, 12
Paravalvular leaks2011-12
Ø46 patients with aortic or mitral leaksØAges 29-84 yearsØ Assessment of Percutaneous Catheter Treatmentof Paravalvular Prosthetic RegurgitationDonald J. Hagler, MD,† Allison K. Cabalka, MD,† Paul Sorajja, MD,* Frank Cetta, MD,† Sunil V. Mankad, MD,* Charles J. Bruce, MD,* Lawrence J. Sinak, MD,*Krishnaswamy Chandrasekaran, MD,* Charanjit S. Rihal, MD*JACC: Cardiovascular Imaging 2010; 3:88-91
Ø Long-Term Follow-Up of Percutaneous Repair of Paravalvular Prosthetic Regurgitation
Sorajja P, Cabalka AK, Hagler DJ, Rihal CSJ Am Coll Cardiol 2011; 58:2218-24
7
Friday, November 2, 12
Paravalvular LeaksJACC 2011
Ø136 total -heart failure, hemolytic anemia
Ø126 patients enrolled in review with 154 defects
ØMean age 67 +/- 12 yrsØ11 pt - unsuccessful (8.7%)ØNo or mild residual 96 (66%)ØModerate residual 30 (24%)
8
Friday, November 2, 12
Paravalvular LeaksØMedical follow up 11 monthsØ3 deaths and 2 strokes in first 30 daysØ29(23%) deaths during follow upØ20(15.8%) had subsequent cardiac
surgeryØ3 yr est survival was 64.5%Øcurrently most commonly use AVPII
§primarily to achieve flat ventricular and atrial disc and the body of the device filling the defect
9
Friday, November 2, 12
Basic ApproachØFemoral venous accessØTranseptal sheath (St Jude Agilis steerable
sheath)ØCross defect with 0.035” extra support
angled Glide wire and telescoped catheter system (6Fr MP Guide, 5Fr MP diagnostic)
ØAdvance 6 Fr MP Guide through defect. If not possible can create an AV loop or use Ventricular puncture to snare if Aortic mechanical prosthesis
Ø Various catheters (up to 8 Fr Shuttle) to place AVP II
Friday, November 2, 12
Imaging
11
Friday, November 2, 12
12
Imaging
Friday, November 2, 12
13
3D TEE
Friday, November 2, 12
ImagingSimultaneous multiple devices
14
Friday, November 2, 12
72 Year Old Female
Referred for Catheter-based Closure of Large Mitral Paravalvular Leak and
associated LV psuedoaneurysm
Friday, November 2, 12
History
ØAortic Stenosis/regurgitation, Mitral regurgitation, and tricuspid regurgitation
Ø2011 (elsewhere): S/P 21 mm St Jude AVR, 25 mm St Jude EPIC tissue MVR, Tricuspid annuloplasty ring/repair, MAZE procedure
ØStormy postop course, >90 day hospitalizationØOngoing CHF symptoms ØHemolytic anemiaØReferred for treatment of paravalvular leak
associated with pseudoaneurysm
Friday, November 2, 12
Pre-Cath Imaging
Friday, November 2, 12
Pre-Cath Imaging
Friday, November 2, 12
Basic Approach
ØFemoral venous accessØTranseptal sheath (St Jude Agilis steerable
sheath)ØCross defect with 0.035” extra support
angled Glide wire and telescoped catheter system (6Fr MP Guide, 5Fr MP diagnostic)
ØEnter pseudoaneurysm and position guide wire; catheter to place AVP II
ØApproach paravalvular defect for definitive closure
Friday, November 2, 12
Friday, November 2, 12
Friday, November 2, 12
Friday, November 2, 12
Friday, November 2, 12
Friday, November 2, 12
Friday, November 2, 12
Friday, November 2, 12
Friday, November 2, 12
Friday, November 2, 12
Friday, November 2, 12
Friday, November 2, 12
Friday, November 2, 12
Friday, November 2, 12
Transeptal Puncture Guidance
Friday, November 2, 12
Transeptal Puncture Guidance
Friday, November 2, 12
Transeptal Puncture Guidance
Friday, November 2, 12
Friday, November 2, 12
Friday, November 2, 12
Friday, November 2, 12
Approach to Pseudoaneurysm
Extra-stiff Angled Glide WireFriday, November 2, 12
Approach to Pseudoaneurysm
Friday, November 2, 12
Approach to Pseudoaneurysm
Friday, November 2, 12
Pseudoaneurysm Closure: 10mm AVP II
Friday, November 2, 12
Pseudoaneurysm Closure: 10mm AVP II
Friday, November 2, 12
Pseudoaneurysm Closure: 10mm AVP II
Friday, November 2, 12
Friday, November 2, 12
Friday, November 2, 12
Friday, November 2, 12
Friday, November 2, 12
Friday, November 2, 12
Friday, November 2, 12
Friday, November 2, 12
Clot Formation in Pseudoaneurysm
Friday, November 2, 12
Clot Formation in Pseudoaneurysm
Friday, November 2, 12
Clot Formation in Pseudoaneurysm
Friday, November 2, 12
Guide for Closure of Paravalve Leak
Glide Wire 6 FR Guide Cath
AVP IIIn
Pseudoaneurysm
Friday, November 2, 12
Friday, November 2, 12
Friday, November 2, 12
Paravalvular Leak Closure: 12 mm AVP II
Friday, November 2, 12
Paravalvular Leak Closure: 12 mm AVP II
Friday, November 2, 12
Paravalvular Leak Closure: 12 mm AVP II
Friday, November 2, 12
Friday, November 2, 12
Friday, November 2, 12
Friday, November 2, 12
Case Resolution
ØOvernight hospitalizationØNo procedural complicationsØDyspnea significantly improved
overnightØEcho showed trivial periprosthetic
regurgitation§Stable bioprosthetic valve function§No effusion
Friday, November 2, 12
Disclosure:Some slides courtesy of Medtronic Corporation Melody® Transcatheter Pulmonary Valve
Melody® and Ensemble® are registered trademarks of Medtronic, Inc.
Melody Valve Percutaneous pulmonary valve
implantation
Friday, November 2, 12
Melody® Valve
ØBovine jugular venous valve segment
ØPlatinum-Iridium stent
Friday, November 2, 12
Melody® Valve
ØBovine jugular venous valve segment
ØPlatinum-Iridium stent
Friday, November 2, 12
Valve Design Rationale
ØUtilizes natural venous valve & vein wall segment
ØDeep coaptation provides competence across range of diameters & geometries
ØThin leaflets open & close under minimal pressure changes
ØVenous wall provides functionality of covered stent
Friday, November 2, 12
Transcatheter Pulmonary Valve
Bonhoeffer P, et al. Lancet 2000
First Human Use
Friday, November 2, 12
ØCircumferential RVOT conduit with > 16 mm diameter at time of original implantation
ØInner diameter < 22 mm
ØRegurgitant and/or stenotic lesions
•> moderate PR•RVOT mean gradient > 35-40 mmHg
Indications The Melody Valve FDA approved under HDE - 2010
Friday, November 2, 12
Clinical History
Revised TPV (2003)
World Wide: >850 patients among >75 centers
2000 2002 2004 2006 2008
1st ImplantParis, France (2000)
CE Mark, Health Canada Approval (2006)
1st US Implant (2007)
Bonhoeffer Cohort(2003-05)
US Cohort (2007-08)
July 2009 FDA Circulatory System Devices Panel July 2009Full Panel Approval
Friday, November 2, 12
Ø22 Fr crossing profileØRetractable sheath
Ensemble® Delivery System
ØBalloon-in-balloon catheter
Ø3 outer balloon diameters§ 18 mm§ 20 mm§ 22 mm
Friday, November 2, 12
TPV Deployment
45
Friday, November 2, 12
Safety ConsiderationsProcedural RisksØCoronary artery
compressionØConduit ruptureØDevice embolization
Device RisksØStent fractureØPulmonary
embolic complications
ØEndocarditis
Friday, November 2, 12
20 yr old PA/VSDMelody® TPV Placement
“PS” velocity – 2 m/sec; Mean gradient 10 mmHgTR velocity 2.9 m/sec; RVSP 44 mmHg
PR eliminated and ΔRVSP = - 30 mmHg
Friday, November 2, 12
20 yr old PA/VSDMelody® TPV Placement
“PS” velocity – 2 m/sec; Mean gradient 10 mmHgTR velocity 2.9 m/sec; RVSP 44 mmHg
PR eliminated and ΔRVSP = - 30 mmHg
Friday, November 2, 12
20 yr old PA/VSDMelody® TPV Placement
“PS” velocity – 2 m/sec; Mean gradient 10 mmHgTR velocity 2.9 m/sec; RVSP 44 mmHg
PR eliminated and ΔRVSP = - 30 mmHg
Friday, November 2, 12
Freedom From Stent FractureError bars are 95% confidence limits
Months 0 3 6 9 12 14N at risk 89 77 52 36 29 9N at risk 89 74 47 28 24 8
Free
dom
from
Eve
nt
0.2
0.4
0.6
0.8
1.0
U.S. Study
Major All
6 months 12 Months
FF Major stent fracture 99% 91%FF All stent fracture 89% 77%
Major
All
0.0
Friday, November 2, 12
Type I Type II Type III Stent Fracture Examples
U.S. Study
Fragmentation with embolization:
One observed in U.S. Study
Friday, November 2, 12
Type I Type II Type III Stent Fracture Examples
U.S. Study
Fragmentation with embolization:
One observed in U.S. Study
Friday, November 2, 12
Type I Type II Type III Stent Fracture Examples
U.S. Study
Fragmentation with embolization:
One observed in U.S. Study
Friday, November 2, 12
Type I Type II Type III Stent Fracture Examples
U.S. Study
Fragmentation with embolization:
One observed in U.S. Study
Friday, November 2, 12
Mayo Clinic PatientsØ32 procedures in 31 pts. age 6 - 79 years;
mean 27.7yrsØVarious lesions- TGA, PA, Ross, DORVØ9 homograft conduits; 2 contegra; 20
Tissue prosthesesØ2 Explanted - 1 coronary compression; 1
aortic erosion -stented homograftsØ1 pt -18 y/o at 6 mos had compressed
conduit - had Melody re-implantØAll currently have trivial or no pulmonary
regurgitation - 1 has 38 mm conduit gradient 50
Friday, November 2, 12
Other implantsØ8 patients have had MV implant in a
tissue prothesisØ10 patients have had TV implant in a
tissue prosthesisØAll sucessful resultsØLargest was in 33 mm CE TV
prosthesisØMild Mod MR in one patient, rest had
trivial to no insufficiency
51
Friday, November 2, 12
Stent Compression and FxØTwo 4110 Palmaz Stent and Melody
52
18 Y/O with DORV and contegra graft developed
obstruction in 6 mos
Friday, November 2, 12
re-stented 4110 stents x 3
53
Friday, November 2, 12
Two 4110 Palmaz Stents 22mm Melody valve
54
Friday, November 2, 12
Lessons Learned
55
Friday, November 2, 12
Lessons LearnedØWhen Gradient or RVSP increase during
follow up – suspect TPV fracture
55
Friday, November 2, 12
Lessons LearnedØWhen Gradient or RVSP increase during
follow up – suspect TPV fracture
ØFluoroscopy to detect minor stent fractures
55
Friday, November 2, 12
Lessons LearnedØWhen Gradient or RVSP increase during
follow up – suspect TPV fracture
ØFluoroscopy to detect minor stent fractures
ØOnce noted, ↑ frequency of echo F/U exams to assess for changes in gradient
55
Friday, November 2, 12
Lessons LearnedØWhen Gradient or RVSP increase during
follow up – suspect TPV fracture
ØFluoroscopy to detect minor stent fractures
ØOnce noted, ↑ frequency of echo F/U exams to assess for changes in gradient
ØPrestented or Bioprosthetic conduits have a ↓’d incidence of fracture
55
Friday, November 2, 12
Lessons LearnedØWhen Gradient or RVSP increase during
follow up – suspect TPV fracture
ØFluoroscopy to detect minor stent fractures
ØOnce noted, ↑ frequency of echo F/U exams to assess for changes in gradient
ØPrestented or Bioprosthetic conduits have a ↓’d incidence of fracture
Ø“Repeat” TPV has been effective in relieving fracture related PS
55
Friday, November 2, 12
Lessons LearnedØWhen Gradient or RVSP increase during
follow up – suspect TPV fracture
ØFluoroscopy to detect minor stent fractures
ØOnce noted, ↑ frequency of echo F/U exams to assess for changes in gradient
ØPrestented or Bioprosthetic conduits have a ↓’d incidence of fracture
Ø“Repeat” TPV has been effective in relieving fracture related PS
ØLate performance of 2nd TPV is still to be determined
55
Friday, November 2, 12
Conclusions
ØIntermediate term function of the Melody® TPV is good§ Improved PR, RVSP, RV dilation,
RVOT gradient, and NYHA class• Very little clinically important PR
§Recurrent PS is rare except in those with stent fractures• (Pre-stenting landing zone should
impact this favorably)
Friday, November 2, 12
VSD Closure
Ø59 y/o male S/P AVR with 25 mm Carbomedics Aortic Mechanical prosthesis
ØS/P LIMA LAD bypass graftØS/P attempted surgical repair of VSDØDDD pacing system for CHB after AVRØResidual VSD with LV to RV/RA shunt
Friday, November 2, 12
VSD Closure
Friday, November 2, 12
VSD Closure
Friday, November 2, 12
VSD Closure
Friday, November 2, 12
VSD Closure
Friday, November 2, 12
VSD Closure
Friday, November 2, 12
VSD Closure
Friday, November 2, 12
VSD Closure
Friday, November 2, 12
VSD Closure
Friday, November 2, 12
ICE
Friday, November 2, 12
ICE
Friday, November 2, 12
ICE
Friday, November 2, 12
Hemodynamics
Friday, November 2, 12
SVC approach – ICE guidance
Friday, November 2, 12
SVC approach – ICE guidance
Friday, November 2, 12
SVC approach – ICE guidance
Friday, November 2, 12
Transseptal with left Judkins
Friday, November 2, 12
Wire snared into IVC
Friday, November 2, 12
10 mm Amplatz VSD occluder
Friday, November 2, 12
10 mm Amplatz VSD occluder
Friday, November 2, 12
10 mm VSD
Friday, November 2, 12
10 mm VSD
Friday, November 2, 12
Post VSD closure
Friday, November 2, 12
Post VSD closure
Friday, November 2, 12
Post VSD closure
Friday, November 2, 12
SummaryInterventional progress
70
ØInitally Balloon valvotomy, angioplasty, Vascular stents
ØClosure devices: ASD, PDA, VSDØParavalvular leak closures - AVPII, AVPIII
not yet available in US.ØPercutaneous Melody valve implant
§ Expanded to Tricuspid, MitralØNew smaller percutaneous, pulmonary
and aortic valve implants -14 FrenchØGreater use of CT and Rotational
Angiography and 3D EchocardiographyFriday, November 2, 12
THANK YOU
Friday, November 2, 12
Friday, November 2, 12